Alliance to Zero founded to achieve net zero emissions across the pharmaceutical supply chain

News – Ypsomed Delivery Systems

Burgdorf – Today, eight companies representing the pharmaceutical supply chain for pharma products announced the founding of the Alliance to Zero, a non-profit membership association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net zero emissions in line with the goals of the Paris Climate Agreement.

Compelling design enables simple adherence monitoring

News – Ypsomed Delivery Systems

Ypsomed has been successful in the Red Dot Award: Product Design 2021. An international jury of experts has awarded SmartPilot for the UnoPen pen injector the distinction “Red Dot”, which stands for high design quality.

News – Ypsomed Delivery Systems

Burgdorf / Mainz / Basel – Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment.

World's first zero carbon emission autoinjector from Ypsomed

News – Ypsomed Delivery Systems

Burgdorf – Ypsomed has developed the world’s first zero carbon emission prefilled autoinjector. The YpsoMate Zero is based on the proven YpsoMate autoinjector platform that offers convenient handling and patient safety. The new YpsoMate Zero uses alternative biopolymers and a novel packaging design that follows the principles of circular product design.

Ypsomed's autoinjector YpsoMate

Promising start-up opts for Ypsomed's user-friendly autoinjector to treat PMDD

News – Ypsomed Delivery Systems

Asarina Pharma has decided to go with our user-friendly two-step autoinjector YpsoMate for its commercial launch of its drug Sepranolone. Sepranolone is the world’s first treatment for pre-menstrual dysphoric disorder (PMDD).

Teva has announced the launch of AJOVY in an autoinjector device for the German market in March 2020.
AJOVY autoinjector

News – Ypsomed Delivery Systems

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.

Market entry of YpsoMate autoinjector for Teribone™ in Japan
Teribone™ autoinjector

News – Ypsomed Delivery Systems

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and will be launched in Japan.

YpsoDose patch injector in use

Satisfied user study participants

News – Ypsomed Delivery Systems

YpsoDose is a patch injector for large volumes. When developing YpsoDose, we focus on user-friendliness as we do with all our injection systems. The latest user studies have confirmed how easy YpsoDose is to use. 

Ypsomed's autoinjector YspoMate

YpsoMate's platform approach is paying off

News – Ypsomed Delivery Systems

Several customers have recently launched their autoinjectors based on our YpsoMate platform product technology on the market. Customers value the fast product customisation as well as the individual design possibilities. End users appreciate its user-friendliness.

Copaxone PEN from Teva

News – Ypsomed Delivery Systems

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the
second commercial market entry of Ypsomed’s autoinjector YpsoMate®.